AvalehtJAZZ • NASDAQ
add
Jazz Pharmaceuticals PLC
113,00 $
Pärast sulgemist:(0,00%)0,00
113,00 $
Suletud: 10. juuni, 17:20:00 GMT −4 · USD · NASDAQ · Välistus
Viimane sulgemishind
111,87 $
Tänane vahemik
111,33 $ - 114,30 $
Aasta vahemik
95,49 $ - 148,06 $
Turuväärtus
6,96 mld USD
Keskmine maht
1,18 mln
P/E suhe
15,06
Dividendimäär
-
Põhibörs
NASDAQ
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (USD) | märts 2025info | Y/Y muutus |
|---|---|---|
Käive | 897,84 mln | −0,46% |
Põhitegevusega seonduv kulu | 849,11 mln | 16,27% |
Puhastulu | −92,54 mln | −533,06% |
Puhaskasumimarginaal | −10,31 | −536,42% |
Puhaskasum aktsia kohta | 1,68 | −37,31% |
EBITDA | 138,86 mln | −48,29% |
Tõhus maksumäär | 16,14% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (USD) | märts 2025info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 2,57 mld | 41,05% |
Kogu vara | 11,53 mld | 1,83% |
Kõik kohustused | 7,36 mld | −3,55% |
Kogu omakapital | 4,17 mld | — |
Emiteeritud aktsiate arv | 61,63 mln | — |
Hinna ja väärtuse suhe P/B | 1,65 | — |
Varade tasuvus | −0,55% | — |
Kapitali tasuvus | −0,65% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (USD) | märts 2025info | Y/Y muutus |
|---|---|---|
Puhastulu | −92,54 mln | −533,06% |
Põhitegevuse rahakäive | 429,78 mln | 60,83% |
Investeeringute raha | −168,93 mln | 37,87% |
Finantseerimise raha | −813,47 mln | −1 338,44% |
Raha ja raha ekvivalentide muutus | −550,92 mln | −775,52% |
Tasuta rahavoog | 408,56 mln | 17,62% |
Teave
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
Tegevjuht
Asutatud
2003
Veebisait
Töötajate arv
2 800
